2-Deoxy-D-glucose (2-DG): Precision Glycolysis Inhibition for Cancer and Immunometabolism Research

Executive Summary: 2-Deoxy-D-glucose (2-DG) is a glucose analog that competitively inhibits glycolysis, thereby reducing ATP synthesis in mammalian cells (Wang et al., 2021). This compound demonstrates cytotoxicity in KIT-positive gastrointestinal stromal tumor cell lines at micromolar concentrations in vitro (APExBIO, B1027). 2-DG modulates immune cell metabolism, suppressing T-cell proliferation via downregulation of mTOR/HIF1α/LDHA signaling (Wang et al., 2021). In animal models, 2-DG enhances the efficacy of chemotherapeutics, slowing tumor growth in xenografts. The B1027 kit from APExBIO is engineered for robust solubility and workflow integration, supporting reproducible metabolic pathway research (see mechanistic review).

Biological Rationale

2-Deoxy-D-glucose (2-DG, also referred to as 2 deoxyglucose, 2 d glucose, or 2 deoxy d glucose 2 dg) is a structural analog of glucose. It enters cells via glucose transporters, then becomes phosphorylated but cannot proceed through glycolysis (Wang et al., 2021). Many cancer cells and activated immune cells rely on increased glycolytic flux for energy and biosynthetic precursors, a phenomenon termed the 'Warburg effect' (Wang et al., 2021). Inhibiting glycolysis selectively impacts rapidly proliferating cells, making 2-DG a valuable tool in oncology and immunology research. By targeting glycolytic metabolism, 2-DG also induces metabolic oxidative stress, leading to altered cell fate decisions. This mechanism underpins its relevance in cancer, autoimmunity, and antiviral studies (see application overview).

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

2-DG is transported into cells by facilitative glucose transporters (GLUTs). Following uptake, hexokinase phosphorylates 2-DG to 2-DG-6-phosphate, which cannot be further metabolized by phosphoglucose isomerase. This leads to accumulation of 2-DG-6-phosphate, feedback inhibition of glycolysis, decreased lactate production, and reduced ATP synthesis (Wang et al., 2021). In activated T cells, inhibition of glycolysis by 2-DG results in suppressed LDHA, p-mTOR, and HIF1α expression, reducing cell proliferation and promoting apoptosis (Wang et al., 2021). In viral infection models, 2-DG impairs early-stage viral protein translation and genome replication by disrupting host ATP and glycosylation pathways (APExBIO, B1027).

Evidence & Benchmarks

• 2-DG reduces T-cell proliferation and increases apoptosis by inhibiting LDHA and mTOR/HIF1α/PLD2 signaling in OLP lesions (DOI:10.1111/jcmm.16964).
• 2-DG displays in vitro cytotoxicity against KIT-positive gastrointestinal stromal tumor cell lines with IC50 values of 0.5 μM (GIST882) and 2.5 μM (GIST430) (APExBIO, B1027).
• In animal models, co-administration of 2-DG with chemotherapeutics (Adriamycin, Paclitaxel) significantly slows tumor growth in xenografts of osteosarcoma and non-small cell lung cancer (APExBIO, B1027).
• 2-DG inhibits porcine epidemic diarrhea virus (PEDV) replication and viral protein translation in Vero cells during early infection (APExBIO, B1027).
• Typical experimental conditions utilize 5–10 mM 2-DG for 24 hours in cell-based assays; compound is soluble at ≥105 mg/mL in water (APExBIO, B1027).

This article extends the mechanistic details presented in 2-Deoxy-D-glucose: Mechanistic Innovation in Cancer, Immunology and Virology by providing updated, quantitative benchmarks and clarifying workflow parameters for reproducibility.

Applications, Limits & Misconceptions

2-DG is widely utilized in metabolic pathway research, cancer therapy investigations, immunometabolism, and antiviral studies. As a glycolysis inhibitor, it enables dissection of metabolic reprogramming in both malignant and immune cells (see scenario-driven solutions). In translational models, 2-DG potentiates chemotherapeutic responses and promotes metabolic oxidative stress. In virology, 2-DG has demonstrated efficacy in inhibiting early-stage viral replication by suppressing energy supply and glycosylation-dependent processes (APExBIO, B1027).

Common Pitfalls or Misconceptions

• Non-specific toxicity: 2-DG can induce metabolic stress in non-targeted, highly proliferative normal cells; careful titration and cell-type selection are required.
• Lack of efficacy in quiescent cells: Cells relying primarily on oxidative phosphorylation exhibit minimal sensitivity to 2-DG.
• Reversibility: Glycolysis inhibition by 2-DG is reversible upon compound removal; long-term effects require continuous presence.
• Solubility artifacts: Incomplete dissolution in ethanol or DMSO without warming/sonication can lead to inconsistent results.
• Not a universal antiviral: 2-DG's efficacy is context-dependent and does not broadly suppress all viruses; activity is pronounced in viruses reliant on host glycolysis.

This review clarifies and updates the troubleshooting insights found in 2-Deoxy-D-glucose: Precision Glycolysis Inhibitor for Translational Models by delineating specific mechanistic and workflow boundaries for 2-DG application.

Workflow Integration & Parameters

2-DG is supplied as a powder (SKU B1027) by APExBIO and achieves solubility of ≥105 mg/mL in water, ≥2.37 mg/mL in ethanol (with warming/sonication), and ≥8.2 mg/mL in DMSO (2-Deoxy-D-glucose (2-DG), APExBIO). Stock solutions should be aliquoted and stored at −20°C; avoid long-term storage of working solutions. Typical in vitro protocols employ 5–10 mM 2-DG for 24-hour treatments. For in vivo or translational workflows, dose and route should be optimized based on tumor type, animal model, and combination regimens (see workflow optimization—this article adds new quantitative evidence for parameterization in immune and viral systems).

Conclusion & Outlook

2-Deoxy-D-glucose (2-DG) is a rigorously validated tool for glycolysis inhibition in cancer, immunometabolic, and antiviral research. Its atomic mechanism—blocking the glycolytic flux and ATP synthesis—enables targeted studies of metabolic vulnerabilities in rapidly dividing cells. The B1027 kit from APExBIO provides reliable, reproducible performance for advanced experimental workflows. Ongoing studies are refining optimal parameters for combination therapies and expanding the clinical translation of 2-DG as a metabolic oxidative stress inducer. Researchers should remain aware of its cell-type selectivity and experimental boundaries to maximize utility and minimize artifacts (product details).